Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma

Molecular Carcinogenesis

Volumn 36, Issue 2, 2003, Pages 53-59

  Jazaeri, Amir A ^a,e   Lu, Karen ^b   Schmandt, Rosemarie ^b   Harris, Charles P ^c   Rao, Pulivarthi H ^c   Sotiriou, Christos ^a   Chandramouli, G V R ^a   Gershenson, David M ^b   Liu, Edison T ^a,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c TEXAS CHILDREN S CANCER CENTER   (United States)

^d GENOME INSTITUTE OF SINGAPORE   (Singapore)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

20q13; Centrosome; Grade; Microarray; Ovarian cancer

Indexed keywords

AMPLICON; ARTICLE; CANCER GRADING; CENTROSOME; CHROMOSOME 20Q; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENETICS; HISTOLOGY; HUMAN; HUMAN TISSUE; INTERPHASE; ONCOGENE; OVARY CANCER; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; TUMOR DIFFERENTIATION;

CARCINOMA, PAPILLARY; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROTEIN ARRAY ANALYSIS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 0037311764     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.10098     Document Type: Article

References (37)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Balli S, Fey MF, Hanggi W, et al. Ovarian cancer. An institutional review of patterns of care, health insurance and prognosis. Eur J Cancer 2000;36:2061-2068.
3. Vergote I, De Brabanter J, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001;20;357:176-182.
4. Malkasian GD Jr, Melton U III, O'Brien PC, Greene MH. Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am J Obstet Gynecol 1984;149:274-284.
5. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974-979.
6. DeRisi J, Penland L, Brown PO, et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 1996;14:457-460.
7. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 1999;286:531-537.
8. Wang K, Gan L, Jeffery E, et al. Monitoring gene expression profile changes in ovarian carcinomas with cDNA microarray. Gene 1999;229:101-108.
9. Welsh JB, Zarrinkar PP, Sapinoso LM, et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 2001;98:1176-1181.
10. Russell P. The pathologic assessment of ovarian neoplasms. III: The malignant "epithelial" tumours. Pathology 1979;11:493-532.
11. Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD, Eberwine JH. Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci USA 1990;87:1663-1667.
12. http://madb.nci.nih.gov/reference/index.shtml ("Alternative Methods and Protocols").
13. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863-14868.
14. Okuda M, Horn HF, Tarapore P, et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 2000;103:127-140.
15. De Souza CP, Ellem KA, Gabrielli BG. Centrosomal and cytoplasmic Cdc2/cyclin B1 activation precedes nuclear mitotic events. Exp Cell Res 2000;257:11-21.
16. Zhou H, Kuang J, Zhong L, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998;20:189-193.
17. Fry AM, Meraldi P, Nigg EA. A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators. EMBO J 1998;17:470-481.
18. Pangilinan F, Li Q, Weaver T, Lewis BC, Dang CV, Spencer F. Mammalian BUB1 protein kinases: Map positions and in vivo expression. Genomics 1997;46:379-388.
19. Ouyang B, Lan Z, Meadows J, et al. Human Bub1: A putative spindle checkpoint kinase closely linked to cell proliferation. Cell Growth Differ 1998;9:877-885.
20. Brinkmann U. CAS, the human homologue of the yeast chromosome-segregation gene CSE1, in proliferation, apoptosis, and cancer. Am J Hum Genet 1998;62:509-513.
21. De Angelis PM, Clausen OP, Schjolberg A, Stokke T. Chromosomal gains and losses in primary colorectal carcinomas detected by CGH and their associations with tumour DNA ploidy, genotypes and phenotypes. Br J Cancer 1999;80:526-535.
22. Forozan F, Mahlamaki EH, Monni O, et al. Comparative genomic hybridization analysis of 38 breast cancer cell lines: A basis for interpreting complementary DNA microarray data. Cancer Res 2000;60:4519-4525.
23. Suehiro Y, Sakamoto M, Umayahara K, et al. Genetic aberrations detected by comparative genomic hybridization in ovarian clear cell adenocarcinomas. Oncology 2000;59:50-56.
24. Suzuki S, Moore DH, Ginzinger DG, et al. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res 2000;60:5382-5385.
25. Tanner MM, Grenman S, Koul A, et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res 2000;6:1833-1839.
26. Wang R, Lu YJ, Fisher C, Bridge JA, Shipley J. Characterization of chromosome aberrations associated with soft-tissue leiomyosarcomas by twenty-four-color karyotyping and comparative genomic hybridization analysis. Genes Chromosomes Cancer 2001;31:54-64.
27. Phillips JL, Hayward SW, Wang Y, et al. The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. Cancer Res 2001;61:8143-8149.
28. Collins C, Volik S, Kowbel D, et al. Comprehensive genome sequence analysis of a breast cancer amplicon. Genome Res 2001;11:1034-1042.
29. Savelieva E, Belair CD, Newton MA, et al. 20q gain associates with immortalization: 20q 13.2 amplification correlates with genome instability in human papillomavirus 16 E7 transformed human uroepithelial cells. Oncogene 1997;14:551-560.
30. Cuthill S, Agarwal P, Sarkar S, Savelieva E, Reznikoff CA. Dominant genetic alterations in immortalization: Role for 20q gain. Genes Chromosomes Cancer 1999;26:304-311.
31. Nonet GH, Stampfer MR, Chin K, Gray JW, Collins CC, Yaswen P. The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells. Cancer Res 2001;61:1250-1254.
32. Masselink H, Vastenhouw N, Bernards R. B-myb rescues rasinduced premature senescence, which requires its transactivation domain. Cancer Lett 2001;171:87-101.
33. Lyon J, Robinson C, Watson R. The role of Myb proteins in normal and neoplastic cell proliferation. Crit Rev Oncog 1994;5:373-388.
34. Sala A, Watson R. B-Myb protein in cellular proliferation, transcription control, and cancer: Latest developments. J Cell Physiol 1999;179:245-250.
35. Goepfert TM, Brinkley BR. The centrosome-associated Aurora/Ipl-like kinase family. Curr Top Dev Biol 2000;49:331-342.
36. Boveri T. The origin of malignant tumors. 1929, Baltimore, MD: William & Wilkins Co.
37. Bakshi N, Rajwanshi A, Patel F, Ganguly NK. Prognostic significance of DNA ploidy and S-phase fraction in malignant serous cystadenocarcinoma of the ovary. Anal Quant Cytol Histol 1998;20:215-220.